Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis (MiFlaPRO)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04335617 |
Recruitment Status :
Recruiting
First Posted : April 6, 2020
Last Update Posted : November 3, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Proctitis Radiation | Drug: MMPF (Micronized purified Flavonoid-Fraction) Other: Placebo | Phase 3 |
Radiation proctitis is an inflammation of rectal mucosa, a complication following radiation therapy for cancers of the prostate, cervix, uterus, bladder and other malignancies in the pelvic area. Around 20 % of radiation patients develop radiation proctitis. There is a significant lack of trial treatments for radiation proctitis, even more, the studies often are small and single center designed or case series. In 2 recent reviews pointing out the management of radiation proctitis (2018 and 2016) a summary of current options in therapy according to current scientific knowledge is given. Unfortunately, these studies are about interventional options with the serious risk of complication. Only little data and lack of significance in smaller series on conservative strategies are given.
The goal of the trial is to implement a specific medication in the management and every grade of radiation proctitis - concomitant to eventual need of MMPF is described with potent anti-inflammatory mucosal capacity reducing bleeding, pain and urgency symptoms in patients with hemorrhoidal and/or postoperative symptoms. By using a placebo instead of comparative oral medications (with low evidence) this study might illustrate clinical significance of expected results as well as information on the natural history of radiation proctitis.
The goal of the study is to compare the number of necessary interventions required to stop bleeding in chronic radiation proctitis in patients receiving MMPF in comparison to patients in the control group receiving Placebo within 12 months of medical treatment.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | This is a multicenter, randomized, double-blind, placebo-controlled Phase III study. |
Masking: | Double (Participant, Investigator) |
Masking Description: | In this double blinded study Daflon and placebo are packed in the same manner, the blind is also protected by randomization. Only the principal investigator can break the blind in case of ethical or threatening patterns by contacting the sponsor and clinical research item. |
Primary Purpose: | Treatment |
Official Title: | A Multicenter, Randomized, Double Blind Placebo Controlled Trial of Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis |
Actual Study Start Date : | February 26, 2020 |
Estimated Primary Completion Date : | February 26, 2023 |
Estimated Study Completion Date : | August 26, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Investigational
Patients receive MMPF 500mg for one year
|
Drug: MMPF (Micronized purified Flavonoid-Fraction)
500mg film-coated tablet, oral route, tablets should be taken at meal times. 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily, one at midday and one in the evening |
Placebo Comparator: Placebo
Patients receive Placebo for one year
|
Other: Placebo
4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily |
- Number of necessary intervention [ Time Frame: Day 1- Day 360 ]Interventions to stop acute bleeding by chronic radiation proctitis: surgical, endoscopic or proctoscopic interventions
- Quality of life of patients [ Time Frame: Day 0 Day 180 Day 360 ]Differences in quality of life of patients will be measured with evaluation of two questionnaires (EORTC QLQ C30 & PRT20). Higher scores mean a better quality of life.
- Blood samples [ Time Frame: Day 0-Day 360 ]Differences in serum hemoglobin, thrombocytes, coagulation parameters (quick/pt=prothrombin time)
- Stool [ Time Frame: Day 0-Day 360 ]Differences in calprotectin stool level
- Presence of histological alterations [ Time Frame: Day 0-Day 360 ]Differences in histological alterations (distortion of crypts, Inflammation of crypts, fibrosis and ectasia of vessels, cytokines)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- signed informed consent form
- male and female patients
- age ≥ 18 years
- patients with diagnosis of radiation proctitis with macroscopic bleeding
- end of radiotherapy ≥ 3 month = 90 days ago
Exclusion Criteria:
- infectious proctitis
- ulcerative proctitis (inflammatory bowel disease)
- persons unable to understand the informed consent
- persons, who are in dependent relationship with the study investigators or Sponsor
- pregnant or lactating women
- participation in an interventional study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04335617
Contact: Irmgard Kronberger, MD | +43 512 504 ext 0 | irmgard.kronberger@i-med.ac.at | |
Contact: Marijana Ninkovic, MD | +43 512 504 ext 0 | marijana.ninkovic@i-med.ac.at |
Austria | |
Medizinische Universität Innsbruck | Recruiting |
Innsbruck, Tyrol, Austria, 6020 | |
Contact: Irmgard E Kronberger, MD irmgard.kronberger@i-med.ac.at | |
Krankenhaus der Stadt Dornbirn | Not yet recruiting |
Dornbirn, Austria, 6850 | |
Contact: Clemens Obwegeser, Dr. | |
Barmherzige Brüder Krankenhaus Graz | Recruiting |
Graz, Austria, 8020 | |
Contact: Martin Mitteregger, Dr. | |
Medizinische Universität Graz | Recruiting |
Graz, Austria, 8036 | |
Contact: Martina Lemmerer, Dr. | |
Universitätsklinikum Krems | Recruiting |
Krems, Austria, 3500 | |
Contact: Stefan Sattler, Dr. | |
Ordensklinikum Linz GmbH Elisabethinen | Recruiting |
Linz, Austria, 4020 | |
Contact: Ulrike Enkner, Dr. | |
Kepleruniversität Linz | Recruiting |
Linz, Austria, 4040 | |
Contact: Günther Klimbacher, Dr. | |
Universitätsklinikum Tulln | Recruiting |
Tulln, Austria, 3430 | |
Contact: Alf-Dorian Binder, Dr. | |
Salzkammergut Klinikum Vöcklabruck | Recruiting |
Vöcklabruck, Austria, 4840 | |
Contact: Raimund Strouhal, Dr. | |
Medizinische Universität Wien | Recruiting |
Wien, Austria, 1090 | |
Contact: Stefan Riss, Assoc.-Prof. | |
Krankenhaus Nord, Klinik Floridsdorf | Recruiting |
Wien, Austria, 1210 | |
Contact: Zacaria Sow, Dr. |
Responsible Party: | Irmgard E Kronberger, MD, Principle Investigator, Medical University Innsbruck |
ClinicalTrials.gov Identifier: | NCT04335617 |
Other Study ID Numbers: |
MiFlaPRO_2019 |
First Posted: | April 6, 2020 Key Record Dates |
Last Update Posted: | November 3, 2020 |
Last Verified: | October 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Proctitis Gastroenteritis Gastrointestinal Diseases |
Digestive System Diseases Rectal Diseases Intestinal Diseases |